Patient-reported outcomes following primary total hip arthroplasty in Crowe type III or IV developmental dysplasia are comparable to those in Crowe type I: a case-control study of 96 hips with intermediate-term follow-up

Table 2 The Net promoter score in each group

Groups	Promoters	Passives	Detractors	NPS
H group (n = 23)	69.5% (n = 16)	26.1% (n = 6)	4.3% (n = 1)	65
Control (n = 46)	80.4% (n = 37)	10.9% (n = 5)	8.7% (n = 4)	72
FO group (n = 10)	70.0% (n = 7)	20.0% (n = 2)	10.0% (n = 1)	60
N-FO group (n = 12)	75.0% (n = 9)	25.0% (n = 3)	0% (n = 0)	75

On the 0–100 scale, patients scoring above 90 were classified as “promoters”, between 70 and 89 were classified as “passives” and under 70 were classified as “detractors”. The NPS was calculated by subtracting the percentage of “detractors” from the percentage of “promoters”
NPS Net promoter score, FO group femoral shortening osteotomy group, N-FO group non-femoral shortening osteotomy group

ISSN: 1471-2474